Melanoma

As one of the first skin cancer treatment programs in New York City, we have long been at the forefront of melanoma research and care. We created the ABCDE screening system—now a standard diagnostic tool—to help identify melanoma at an early stage, when treatment is most effective.

Our dermatologists, dermatopathologists, oncologic surgeons, reconstructive plastic surgeons, medical oncologists, radiation oncologists, and pathologists combine their expertise to customize a treatment plan for you.

Our melanoma surgeons specialize in removing the cancer while preserving appearance and function, and our medical oncologists provide the latest targeted treatments, including genetically engineered injectable therapies.

Clinical Trials and Research Studies

Phase 5

Phase I/II study of dabrafenib trametinib and navitoclax in BRAF mutant melanoma (Phase I and II) and other solid tumors (Phase I only).

Learn More

Phase 2

A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST) KEAP1/NRF2 and LKB1 Aberrant Tumors

Learn More

Phase 2

A Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas Cutaneous Squamous Cell Carcinoma Merkel Cell Carcinoma and Other Rare Skin Tumors

Learn More

Phase 2

A Randomized Controlled Open-Label Phase 2 Study of Cemiplimab as a Single Agent and in Combination with RP1 in Patients with Advanced Cutaneous Squamous Cell Carcinoma

Learn More